

T: 0131-244 2528

E: irene.fazakerley@scotland.gsi.gov.uk



IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

3 June 2013

Dear Healthcare Professional,

DRUG ALERT CLASS 2 15 ACTION WITHIN 48 HOURS

Please see the attached drug alert for onward transmission as below.
Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

1. Please could Medical Directors forward this alert to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY

Finance, e-Health and Pharmaceuticals Directorate

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours
Pharmacy, Clinic and Wholesaler Level Recall

Date: 03 June 2013

EL (13)A/15

Our Ref: MDR 80-05/13

Dear Healthcare Professional,

Bristol-Myers Squibb Pharmaceuticals Limited

Questran 4g sachet Powder for Oral Suspension Colestyramine Powder for Oral Suspension

PL 00125/5009R

Bristol-Myers Squibb Pharmaceuticals Limited (BMS) is recalling, as a precautionary measure, all lots of the sucrose containing formulation of Questran (colestyramine) Powder for Oral Suspension, that are within expiry date, due to possible contamination with *Enterococcus faecium*.

The source of the possible contamination is believed to be the sucrose used within this formulation of Questran.

To date the presence of *Enterococcus faecium* has not been detected in commercial batches of Questran, and there have been no product complaints or reported adverse health events in connection with this issue.

Please note that Questran Light is unaffected by this recall.

Remaining stocks of any Questran batches should be quarantined and returned to the original supplier for credit.

For medical information enquiries please contact BMS by phone on 0800 731 1736 or by email to medical.information@bms.com.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.

Yours faithfully

Adam Burgess
DMRC Manager

Defective Medicines Report Centre
151 Buckingham Palace Road
London
SW1W 9SZ
Telephone +44 (0)20 3080 6574